Keratoacanthoma: Facts and controversies

Ko, Christine J.

doi:10.1016/j.clindermatol.2009.06.010

Cited by 77 publications

(76 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relationship between keratoacanthoma and SCC is controversial, with keratoacanthoma showing evidence of altered pathophysiology and CD8 + immune response. 52 These findings have potential clinical implications. Taken with previous findings, stratification of RTRs by CD57 expression prior to commencement of immunosuppression may allow for tailored education and surveillance with regard to the risk of future malignancy, especially in those triaged as high risk by clinical risk scores.…”

Section: Discussionmentioning

confidence: 97%

CD8+ Immunosenescence Predicts Post-Transplant Cutaneous Squamous Cell Carcinoma in High-Risk Patients

Bottomley

Harden

Wood

2015

JASN

View full text Add to dashboard Cite

Most morbidity associated with malignancy in long-term renal transplant recipients is due to cutaneous squamous cell carcinoma (SCC). Previously identified measures to stratify SCC risk have limited use, however. We hypothesized that an increased proportion of senescent, terminally differentiated CD8 + T cells would identify renal transplant recipients at elevated SCC risk. Peripheral blood lymphocytes were isolated from 117 stable transplant recipients at high risk of SCC and analyzed phenotypically by flow cytometry. Participants were followed up prospectively for SCC development. The predictive value of variables was assessed using Cox regression. Age at transplant and enrollment, dialysis duration, and previous disease were predictive of SCC development during follow-up. Previously published clinical phenotype-based risk scores lost predictive value with the removal of age as a covariate. The percentage of CD57-expressing CD8 + T cells was the strongest immunologic predictor of future SCC and correlated with increasing CD8 + T cell differentiation. We dichotomized participants into those with a majority (CD57hi) and a minority (CD57lo) of CD8 + T cells expressing CD57; CD57hi participants were more likely to develop SCC during follow-up (hazard ratio, 2.9; 95% confidence interval, 1.0 to 8.0), independent of potential confounders, and tended to develop earlier recurrence. The CD57hi phenotype was stable with time and associated with increasing age and cytomegalovirus seropositivity. Our results show that the CD57hi phenotype is a strong predictor of SCC development and recurrence in this cohort of long-term, high-risk renal transplant recipients. This information may allow identification of recipients who may benefit from intensive dermatologic screening and immunosuppression reduction.

show abstract

Section: Discussionmentioning

confidence: 97%

CD8+ Immunosenescence Predicts Post-Transplant Cutaneous Squamous Cell Carcinoma in High-Risk Patients

Bottomley

Harden

Wood

2015

JASN

View full text Add to dashboard Cite

show abstract

“…Although KAs are known to be benign, some authors accept them as a variant of SCC. Some KA cases that were initially diagnosed as benign progressed to be metastatic, exhibiting aggressive behavior (3)(4)(5). The immunohistochemical markers that have been used for years to distinguish between SCC and KA in studies are: p53, proliferating cell nuclear antigen , telomerase and COX-2 , transforming growth factor-α, angiotensin-type I receptor, vascular cell adhesion molecule, intercellular adhesion molecule, Ki-67, p16 tumor suppressor antigen, matrix metalloproteinases, syndecan-1 and Bcl-2 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15).…”

mentioning

confidence: 99%

The Role of p16, p21, p27, p53 and Ki-67 Expression in the Differential Diagnosis of Cutaneous Squamous Cell Carcinomas and Keratoacanthomas: An Immunohistochemical Study

et al. 2016

View full text Add to dashboard Cite

“…Mange utvikler keratoakantom, en hudtumor som kan vaere vanskelig å skille fra plateepitelkarsinom (12). Studier har vist en opptil ti ganger økt risiko for basalcellekarsinom (1, 7).…”

Section: Hudkreft Etter Organtransplantasjonunclassified